Frequently asked questions

Photocure markets Hexvix to urologists, hospitals and clinics with its two direct sales forces in North America and in Europe. Outside of these regions, the Company has and plans to continue to license the rights to Hexvix to other commercial healthcare companies in non-core markets. Photocure’s long-term strategy is to expand its product offering in the uro-oncology segment to leverage its two direct commercial organizations in major healthcare markets.

Photocure initially commercialized Hexvix/Cysview in the Nordic countries and in the U.S. The greater European rights to Hexvix were licensed out, first to GE Healthcare and then to Ipsen Pharmaceuticals. Photocure re-acquired the commercial rights to Hexvix in the greater European territories from Ipsen Pharmaceuticals in October 2020. 

Photocure markets Hexvix/Cysview to urologists, hospitals and clinics with its two direct sales forces in North America and in Europe. Outside of these regions, the Company has and plans to continue to license the rights to Hexvix to other commercial healthcare companies in non-core markets. https://www.photocure.com/partners/our-partners

Photocure owns the largest bladder cancer patient registry in the world, with its U.S. real-world evidence study enrolling over 3,100 patients to date and a goal of over 4,000 patients. Between this, other bladder cancer registry studies and Investigator Initiated Trials (IITs), Photocure and bladder cancer researchers continue to generate clinical data that can be presented at medical conferences and published in peer-reviewed articles to support the importance of using of blue light cystoscopy in bladder cancer patient care. This information is important to increase awareness of Hexvix/Cysview, and to expand patient access to blue light cystoscopy internationally. https://www.photocure.com/our-impact/patient-registries-and-real-world-evidence. 

Photocure and Asieris have business relationships for two assets, which were both developed by Photocure. 

1. Cevira: In 2019, Photocure licensed the rights to this drug-device combination for the treatment of pre-cervical cancer cells to Asieris. The product is not core to Photocure’s uro-oncology business, and therefore Asieris has full development and commercialization responsibilities, while Photocure has the opportunity to earn development and sales milestones, as well as royalties on global sales of Cevira, if commercially successful. Questions about Cevira should be directed to Asieris: https://asieris.com/contact/
2. Hexvix: Asieris has also licensed the commercial rights to Photocure’s core bladder cancer product Hexvix for the Chinese and Taiwanese markets. Under this Agreement Photocure and Asieris are partners, and if Hexvix is successfully approved and commercialized in the licensed markets, Photocure is eligible to receive a transfer price on product manufactured and sold to Asieris plus royalties on Asieris’ sales of the product.